Background: Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales are an increasing cause of complicated urinary tract infections (UTIs). Reliance on carbapenems to treat these infections accelerates resistance, underscoring the urgent need for effective oral transition options to preserve last-line agents and lessen healthcare burden. Methods: We conducted a multicenter, open-label, randomized, noninferiority trial at four tertiary hospitals in South Korea (November 2022–June 2025). Adults hospitalized with complicated UTIs due to ESBL-producing Enterobacterales who improved after 3–7 days of intravenous antibiotics were randomized (1:1) to either continue intravenous carbapenem or β-lactam/β-lactamase inhibitor therapy or switch to oral fosfomycin trometamol (3 g once daily). The primary outcome was clinical cure, defined as resolution of urinary tract infection–related symptoms and signs within 4 days after completion of treatment. Secondary outcomes included microbiological cure, readmission, adverse events, and 30-day recurrence. Results: Of the 344 screened patients, 299 were randomized (152 oral fosfomycin; 147 intravenous therapy). Clinical cure occurred in 92.8% of the oral fosfomycin group and 95.2% of the intravenous group (risk difference, −2.47%; 95% CI −7.84 to 2.89), confirming noninferiority. Microbiological cure was similarly high in both groups: urine (98.0% vs 96.6%) and blood (97.3% vs 97.5%). Safety profiles and 30-day outcomes were also comparable. Conclusions: Oral fosfomycin was noninferior to continued intravenous therapy when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales. These findings provide evidence to support oral fosfomycin transition as a carbapenem-sparing antibiotic stewardship strategy for patients with complicated UTIs caused by ESBL-producing Enterobacterales. Clinical Trials Registration: KCT0007669.
1 January 2020 in Journal of Korean Medical Science
A culture of the Leptospira species and the microscopic agglutination test (MAT) are considered as the reference standard for the diagnosis of leptospirosis, but both tests are imperfect for early diagnosis. We describe 4 patients diagnosed with leptospirosis using nested polymerase chain reaction (N-PCR) that targeted the 16S rRNA gene and the passive hemagglutination assay (PHA). In our 4 cases, Leptospira DNA in the urine, plasma, or cerebrospinal fluid (CSF), was detected by N-PCR in the early phase of leptospirosis, except in the sample from the buffy coat. Especially, case 3 showed that N-PCR with the urine and CSF was positive 8 days after symptom onset, but not for the plasma or buffy coat. We report 4 cases of leptospirosis that were diagnosed by N-PCR that targeted the 16S rRNA gene with urine, plasma, or CSF, but not the buffy coat. Three were cured by doxycycline but the case 4 was fatal. Detection of Leptospira DNA by PCR from the urine and CSF, in addition to plasma, may be helpful to confirm the diagnosis.
30 September 2019 in Journal of Oral Medicine and Pain
Bartonella species are vector-borne pathogens that infect a wide range of hosts, including humans. Although several Bartonella species have been identified in rodents and arthropods in Korea, information on Bartonella detection in ticks removed from human patients remains limited. This study investigated the presence of Bartonella species DNA in human-biting ticks collected in Korea and screened for other tick-associated bacteria, including Coxiella endosymbiont. From January to December 2018, 35 ticks were removed from 29 tick-bitten patients in Jeollanam-do and Gwangju, Korea. Ticks were identified morphologically and molecularly by 16S rRNA gene PCR. The presence of Bartonella species was assessed using nested PCR targeting the 16S-23S internal transcribed spacer (ITS) region. The ticks were identified as Haemaphysalis longicornis (17/35, 48.6%), Amblyomma testudinarium (14/35, 40.0%), and Ixodes nipponensis (4/35, 11.4%). Two H. longicornis ticks tested positive for Bartonella species. Sequencing revealed 99.5% identity with B. bacilliformis isolate GJRITS124 in one tick and 98.9% identity with B. taylorii isolate 190731_HC2 in the other, both previously identified in Apodemus agrarius rodents in Korea. One B. bacilliformis-positive tick was also positive for Coxiella spp., and sequence analysis indicated a Coxiella endosymbiont showing 100.0% identity with the Coxiella-like endosymbiont strain 580. Phylogenetic analysis supported these findings; however, bacterial cultures from PCR-positive tick lysates were negative. This study provides baseline evidence of B. bacilliformis and B. taylorii, as well as Coxiella endosymbiont DNA in human-biting H. longicornis ticks in Korea and highlights the need for continued surveillance.